Stockreport

Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

Vor Biopharma Inc.  (VOR) 
PDF Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022Data presented at Keystone Symposia demonstrates significant advancement of novel m [Read more]